370 related articles for article (PubMed ID: 19182722)
1. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.
Jezierska A; Motyl T
Med Sci Monit; 2009 Feb; 15(2):RA32-40. PubMed ID: 19182722
[TBL] [Abstract][Full Text] [Related]
2. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity.
Lunter PC; van Kilsdonk JW; van Beek H; Cornelissen IM; Bergers M; Willems PH; van Muijen GN; Swart GW
Cancer Res; 2005 Oct; 65(19):8801-8. PubMed ID: 16204050
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review).
Yoshizaki T; Sato H; Furukawa M
Oncol Rep; 2002; 9(3):607-11. PubMed ID: 11956636
[TBL] [Abstract][Full Text] [Related]
4. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2.
Nishida Y; Miyamori H; Thompson EW; Takino T; Endo Y; Sato H
Cancer Res; 2008 Nov; 68(21):9096-104. PubMed ID: 18974156
[TBL] [Abstract][Full Text] [Related]
5. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
6. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
7. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
Kuvaja P; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
[TBL] [Abstract][Full Text] [Related]
8. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
9. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells.
Nilsson UW; Garvin S; Dabrosin C
Breast Cancer Res Treat; 2007 May; 102(3):253-61. PubMed ID: 17031577
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer.
Djonov V; Cresto N; Aebersold DM; Burri PH; Altermatt HJ; Hristic M; Berclaz G; Ziemiecki A; Andres AC
Int J Oncol; 2002 Jul; 21(1):25-30. PubMed ID: 12063545
[TBL] [Abstract][Full Text] [Related]
11. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer.
Liu SC; Yang SF; Yeh KT; Yeh CM; Chiou HL; Lee CY; Chou MC; Hsieh YS
Clin Chim Acta; 2006 Sep; 371(1-2):92-6. PubMed ID: 16581051
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
Swellam M; Arab LR; Bushnak HA
IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
[TBL] [Abstract][Full Text] [Related]
13. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Sivula A; Talvensaari-Mattila A; Lundin J; Joensuu H; Haglund C; Ristimäki A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Feb; 89(3):215-20. PubMed ID: 15754118
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
16. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.
Bendrik C; Robertson J; Gauldie J; Dabrosin C
Cancer Res; 2008 May; 68(9):3405-12. PubMed ID: 18451168
[TBL] [Abstract][Full Text] [Related]
18. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2001; 21(3B):2021-8. PubMed ID: 11497292
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]